Why the study?
Does aliskiren/valsartan combination with or without HCT reduce blood pressure in patients with hypertension?
Population
601 patients with hypertension (msDBP ≥ 90 and <110 mmHg)
Design
Cohort, open-label
Follow-up
80 weeks (54-week core phase, 26-week extension phase)
Key result
Aliskiren/valsartan combination with or without HCT provided a mean BP reduction of 20.5/13.4 mmHg at 54 weeks and 28.8/18.3 mmHg at 80 weeks in patients with hypertension.
Authors
Loading...
May support aliskiren/valsartan ± HCT for hypertension; hypothesis-generating and leaves open RCT confirmation.
Does aliskiren/valsartan combination with or without HCT reduce blood pressure in patients with hypertension?
Effect estimate: mean BP reduction of 20.5/13.4 mmHg at 54 weeks
Long-term treatment with aliskiren/valsartan with or without HCT provides clinically meaningful blood pressure reductions and is well-tolerated in patients with hypertension.
Chrysant et al. (2010) studied hypertension (n=601). aliskiren/valsartan combination with or without HCT was evaluated on change in msDBP and msSBP from baseline to endpoint (54-week and 80-week) (mean BP reduction of 20.5/13.4 mmHg at 54 weeks). Aliskiren/valsartan combination with or without HCT provided a mean BP reduction of 20.5/13.4 mmHg at 54 weeks and 28.8/18.3 mmHg at 80 weeks in patients with hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: